Do you deserve to be in the right-hand column?

David Paragamian
David Paragamian
David ­Paragamian
group company president, ApotheCom and ApotheCom ScopeMedical

What does it mean to be truly excellent as a pharmaceutical company or an agency in our business?

I was thinking about this question and I couldn't help but connect to the college search and application process my daughter has been going through this season.  Let me explain.

In my daughter's search process of small, liberal arts colleges, she and her counselor created a three-column list, working left to right: from those that, while still fine schools, were rated easier to gain admission; to middle column schools that were “about right”; and finally, to right hand column schools—the most desirable and the most difficult at which to gain admission.

Having spent my undergraduate years at one of those schools, I also marveled at how, over time, some schools can migrate from one column to another as they gain or lose in perceived prestige and value of their offering.

I tend to think that we live in a business space that can be divided into those three columns. In the left hand column are companies we perceive are less strong, less desirable. It could be weaker pipelines; it could be perceptions about leadership.

There are right hand column companies, too: those with successful, well-positioned  products; robust pipelines and a leadership team and internal corporate  ethos that is admired. Moreover, like colleges that can invest in new presidents, new teaching offerings and new dormitories—and can migrate from one column to another—so can companies.

This same paradigm applies to agency partners. Don't think that client marketing managers and their procurement colleagues don't have the “lists”. There is a reason certain agencies are always on a pitch list. And in this time of incredible change and flux, agency names migrate onto those lists and across those lists as desired partners to marketers in a time of change.

And, like colleges who desire to “migrate,”agencies control their own destiny. It is about good leadership; a strong dedicated team; innovative offerings that are not cookie-cutter to the competitor's offering.

So, bring on the list, and let's earn our place on the right.

You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.